Application of a predictive model of axillary lymph node status in patients with sentinel node metastasis from breast cancer. A retrospective cohort study by Vieni, S. et al.
lable at ScienceDirect
International Journal of Surgery 35 (2016) 58e63Contents lists avaiInternational Journal of Surgery
journal homepage: www.journal-surgery.netOriginal researchApplication of a predictive model of axillary lymph node status in
patients with sentinel node metastasis from breast cancer.
A retrospective cohort study
Salvatore Vieni, Giuseppa Graceffa, Roberta La Mendola, Stefania Latteri, Adriana Cordova,
Mario Adelﬁo Latteri, Calogero Cipolla*
Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italyh i g h l i g h t s In about 60% of patients with metatstic SLN, there is no further axillary neoplastic involvement.
MSKCC nomogram is a valid tool available to select the patients for axillary lymphadenectomy.
 The nomogram has a high reliability and a remarkable utility in clinical practice.a r t i c l e i n f o
Article history:
Received 7 June 2016
Received in revised form
8 September 2016
Accepted 11 September 2016
Available online 12 September 2016
Keywords:
Breast neoplasms
Sentinel lymph node biopsy
Lymphatic metastasis
Axilla
Lymph node excision* Corresponding author. Department of Surgical, O
University of Palermo, Via del Vespro 129, 90127, Pal
E-mail address: calogerocipolla@virgilio.it (C. Cipo
http://dx.doi.org/10.1016/j.ijsu.2016.09.015
1743-9191/© 2016 IJS Publishing Group Ltd. Publisheda b s t r a c t
Background and objectives: The Axillary Lymph Node Dissection (ALND) is the standard treatment in
patients with invasive breast cancer and sentinel node metastasis, but in 60% of the cases there is no
further axillary neoplastic involvement, so this invasive intervention represents an overtreatment. The
purpose of the study is to identify patients with low risk of additional nodal metastases, to omit ALND.
Methods: The MSKCC Additional nodal metastasis nomogramwas applied on a sample of 175 patients with
invasive breast cancer who underwent ALND after detection of macrometastasis with the extempora-
neous examination of the sentinel lymph node. Patients were classiﬁed as “low risk” when the result of
the nomogram was 50%. Sensitivity, speciﬁcity, positive and negative predictive values and AUC (Area
Under Curve) of the ROC curve of the nomogram were then calculated.
Results: A cut-off by 50% yielded 92.3% sensitivity, 81,4% speciﬁcity, 80% positive predictive value and
92.9% negative predictive value. The ROC curve AUC in these patients was 0.885.
Conclusions: The MSKCC nomogram has proven to be an effective tool in estimating the axillary lymph
node status and it can potentially be used to better select the patients with sentinel node macrometa-
stasis who can actually beneﬁt from ALND.
© 2016 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
In patients with invasive breast cancer and clinically negative
axilla, the sentinel lymph node biopsy (SLNB) is considered to be a
safe and reliable tool in the estimation of the neoplastic involve-
ment of axillary lymph nodes and, if it results positive for metas-
tasis, the treatment currently provided in clinical practice is the
axillary lymph node dissection (ALND). However, recent evidencesncological and Oral Sciences,
ermo, Italy.
lla).
by Elsevier Ltd. All rights reserveshow that only in 40% of the cases the sentinel lymph node me-
tastases are associated with a further involvement of the axilla [1]
and that the omission of ALND in patients with tumors character-
ized by favourable histopathological features, no palpable aden-
opathy and 1 to 2 metastatic sentinel lymph nodes is not associated
with a worse prognosis [2,3]. In fact in breast cancer patients with
clinically negative lymph nodes, SLNB alone often seems to repre-
sent a sufﬁcient treatment together with an effective systemic
therapy [4e9]. This leads to the actual need to perform such a
demolitive intervention as ALND, with the risk of complications,
only basing on neoplastic colonization of the sentinel lymph node
(SLN), considering that after surgery patients often undergo adju-
vant therapy, which is an effective tool to ensure adequated.
Table 1
Patient characteristics.








































T1 (2 cm) 88 (50,3%)
T2 (>2 cm e  5 cm) 81 (46,3%)
T3 (>5 cm) 6 (3,4%)
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[10].
To make surgery more conservative and to customize treatment
as much as possible basing on histopathological and biological
features of breast cancer [11], many predictive models have been
developed in order to identify patients who actually beneﬁt from
ALND among those with metastatic SLN. The Additional nodal
metastasis nomogram elaborated by Memorial Sloan- Kettering
Cancer Center (MSKCC) [12] provides a percentage corresponding
to the risk of non-SLN metastasis in SLN-positive patients.
Considering the maneuverability of the nomogram and the easily
accessible information that it requires, the nomogram was applied
to a sample of patients with invasive breast cancer and positive SLN
to assess its sensitivity, speciﬁcity, positive and negative predictive
values. In particular, the possibility of using MSKCC nomogram in
daily clinical practice has been taken into consideration for those
patients at high risk of additional axillary metastasis who undergo
ALND at the same surgical time with tumor excision, distinguishing
them from those to whom ALND can be reasonably omitted
because further axillary involvement is negligible.
2. Materials and methods
2.1. Inclusion criteria of the study
Data on patients who underwent SLNB between January 2009
and June 2015 were collected. All patients received a preoperative
diagnosis of breast cancer conﬁrmed by clinical and instrumental
examinations (mammography and ultrasound) and core biopsy.
200 women with SLN macrometastasis, found with the intra-
operative examination, were selected and subjected to ALND at the
same operative time of tumor resection. 25 patients were elimi-
nated from the sample because 20 of them were characterized by
histological types of invasive breast cancer that are not included in
the nomogram (mucinous, tubular, papillary, mixed types) and the
other 5 for incompleteness of the pathological report. The nomo-
gram was then applied to a total of 175 patients, who meet the
following criteria: invasive ductal or lobular breast cancer preop-
eratively diagnosed bymammography, ultrasound and core biopsy;
clinically negative axillary lymph nodes (N0); detection of macro-
metastases (neoplastic aggregates >2 mm) at intraoperative ex-
amination of SLN performed by frozen section; execution of
complete ALND by the surgeon.
2.2. Patient characteristics
Patient characteristics are different (Table 1). They are all female
and aged between 32 and 86 years for a median age of 55.12 years.
164 of them (93.7%) were subjected to quadrantectomy, the
remaining 11 (6.3%) tomastectomy, both accompanied by SLNB and
subsequent ALND. The histological features of the different cancers
were obtained from a preoperative core biopsy performed on
breast lesions. In all cases, core biopsy provided information that
was fully conﬁrmed by histopathological examination performed
on a surgical specimen, establishing itself as a reliable tool for
preoperative characterization of breast cancers [13,14]. 157 tumors
(89.7%) were ductal type, while only 18 (10.3%) were classiﬁed as
lobular. As regards the histological grade,12 breast cancers were G1
(6.9%), 121 G2 (69.1%) and 42 (24%) were G3.
Core biopsy also provided the gene expression pattern of each
tumor: 158 patients (90.3%) had ER-positive tumors and 17 (9.7%) of
them ER-negative; 148 cancers (84.6%) were PR-positive, 27 (15.4%)
lost PR expression; in 87 cases (49.7%) tumors showed HER2/neu
overexpression, 88 cancers (50.3%) didn't show it.
The last information supplied by core biopsy, then conﬁrmed bythe analysis of the surgical specimen, is the presence of lympho-
vascular invasion, that is the detection of neoplastic cells within
lymphatic and/or blood vessels. 107 tumors of the sample (61.1%)
had lymphovascular invasion, 68 (38.9%) did not.
The dimensions of the tumors, obtained from pre-operative
ultrasound, varies between 0.2 and 7 cm, for a median of 2 cm.
Finally, in 27 patients (15.4%) preoperative imaging showed a
multifocal breast cancer.2.3. Diagnostic and therapeutic procedures and SLN identiﬁcation
Patients in the sample received a preoperative diagnosis of
breast cancer using imaging techniques (mammography and ul-
trasound) and core biopsy which was performed by Lorad® digital
stereotatic table or ultrasound guidance.
The absence of suspicious lymphadenopathy, which is a basic
requirement in order to perform the sentinel lymph node biopsy,
was then checked by means of the clinical and ultrasound exami-
nation of the axilla.
The identiﬁcation of SLN was preoperative and intraoperative.
The day before surgery, all patients underwent lymphoscintigraphy
bymeans of a subareolar injection of Nanocoll (99Tc labelled human
serumalbumin),which is averyaccurate procedure to identifyof the
sentinel lymph node [15,16]. Anterior and anterior-oblique scans
Fig. 1. ROC curve of the nomogram and its AUC.
Fig. 2. Patients distribution into deciles of risk estimated by the nomogram.
Fig. 3. Additional non-SLN positive patient's distribution into deciles of risk estimated
by the nomogram.
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projection of SLN was indicated by a cobalt pen. During surgery, a
gamma probe (Neo2000 Gamma Detection System®) was used in
order to correctly identify and remove all the lymph nodes marked
by the tracer. In a few cases where the radio-guided surgical probe
picked up a weak radiotracer signal, about 10 min before the
beginning of surgery, a subareolar injection of 0.5e0.8 ml of vital
stain (1% lymphazurin) was performed.in order to further improve
the accuracy of the procedure. The excised lymph nodes were then
sent to the pathologist, who ﬁrst performed an intraoperative ex-
amination [17], then the deﬁnitive one. The result of the histo-
pathological intraoperative examination guided the surgeon in
choosing whether or not to complete the surgery with ALND: since
macrometastasisweredetected in all patients, ALNDwasperformed
in all cases. The excised lymph nodes were then examined to asses
their real metastatic involvement.
2.4. Nomogram application
MSKCC nomogram was retrospectively applied to the sample, it
considered for each breast cancer, obtained from pre-operative
imaging, the following characteristics: tumor size, histological
type, number of positive and negative SLN, method of detection of
metastasis, presence/absence of lymphovascular invasion, multi-
focality and ER-status. In all cases, frozen sectionwas indicated as a
method of detection of metastasis. Thanks to the results provided
by the nomogram, the ROC curve was obtained and its Area Under
Curve (AUC), which is an important accuracy index, was calculated.
A cut-off of 50%was set: patients were classiﬁed as “high risk” of
further lymph node metastases if nomogram gave a result >50%,
and as “low risk” if the percentage was 50%. Then the probability
predicted by nomogram was compared with the result of histo-
logical examinations of lymph nodes removed during ALND.
Consequently, false positive and false negative results were coun-
ted and sensitivity, speciﬁcity and positive and negative predictive
values were calculated.
Finally, correlation between each parameter required by the
nomogram and the result provided by the same nomogram was
evaluated using Pearson's coefﬁcient, and then statistical signiﬁ-
cance of each correlation was observed.
3. Results
The probabilities of additional axillary metastasis provided by
MSKCC nomogram range between 21% and 90%. The ROC curve
obtained from the comparison between the results of the nomo-
gram with the results of histological examinations of removed
lymph nodes has an AUC equal to 0.885 (Fig. 1). The division into
deciles of estimated probabilities shows the distribution of patients
of the sample: in most cases a percentage higher than 40% and less
than 70% was obtained (Fig. 2).
Among the 175 patients who underwent ALND, only in 78 cases
(44.6%) there were lymph node metastasis additional to those
localized in SLN. Before calculating the sensitivity and speciﬁcity of
the model using a cut off of 50%, the distribution of patients with
non-sentinel lymph node metastasis into percentage deciles was
evaluated (Fig. 3). The majority of patients with axillary metastasis
is distributed from the sixth decile and a peak is observed between
61% and 70%. The 65.7%, the 93.7%, the 86.7% and the 85.7% of the
patients who fall in the sixth decile, in the seventh decile, in the
eighth decile and in the nineth decile respectively are all charac-
terized by axillary metastases detected at histopathological exam-
ination of the resected lymph nodes.
Once the cut off has been set, cases in which the MSKCC
nomogram provided a percentage >50% were considered “positive”and the ones in which predicted probability was 50% were
considered “negative”. The practical implication of this classiﬁca-
tion is that the “positive” cases, deﬁned at high risk of lymph node
metastasis in addition to those found in the SLN, would be imme-
diately candidated for ALND. On the other hand, in the “negative”
Table 3
Correlation and statistic signiﬁcance for each parametre. LVI ¼ lymphovascular in-
vasion; SLN ¼ sentinel lymph node; ER ¼ estrogene receptor.
Parameter Correlation coefﬁcient (r) P-value
Tumor size 0,5601 <0,0001
LVI 0,5954 <0,0001
Number of positive SLNs 0,5393 <0,0001
Number of negative SLNs 0,4619 <0,0001
Multifocality 0,2362 0,0016
Histological grade 0,1424 0,0616
ER-status 0,2432 0,7494
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lary surgery could be omitted following the purpose of the study,
because it doesn't produce any advantage.
The percentages obtained in 85 patients were 50%, including
the 79 cases (92.9%) in which no further axillary metastasis were
detected, and the 6 cases (7.1%) characterized by additional
metastasis in excised lymph nodes. In the 90 patients in which the
nomogram estimated a probability >50%, 72 cases (80%) of lymph
node metastases were counted, compared to the 18 patients (20%)
without additional axillary metastatic colonization (Table 2).
To sum up, the nomogram achieved the following results: 80% of
true positives, which corresponds to the positive predictive value of
the model; 20% of false positives; 92.9% of true negatives, which
corresponds to the negative predictive value of the model; 7.1% of
false negatives. Sensitivity and speciﬁcity of the MSKCC nomogram
applied to the sample were then calculated: sensitivity was 92.3%
and speciﬁcity was 81,4%.
As regards the correlation between each of the parameters
required by the nomogram and the probability predicted from it
(Table 3), tumor characteristics in direct correlation with the result
provided by the nomogram are tumor size, the presence of lym-
phovascular invasion, the number of positive SLNs, multifocality
and histological grade; on the other hand, the number of negative
SLNs and ER-status are in inverse correlation with the probability
provided by the model. The index that best positively correlates
with the percentage provided by the nomogram is the lympho-
vascular invasion, followed by tumor size, number of positive SLNs,
the multifocality and ﬁnally histological grade. All of these pa-
rameters have a statistically signiﬁcant correlation (P-value <0.05),
except for the histological grade. Among the parameters charac-
terized by inverse correlation, only the number of SLNs is nega-
tively correlated in a statistically signiﬁcant way to the result
provided by the nomogram.
4. Discussion
The results obtained from the application of MSKCC nomogram
to patients of the sample are extremely signiﬁcant: it shows great
effectiveness in predicting the presence of lymph node metastases
in addition to those found at intraoperative examination of the SLN.
An optimal staging has a role also in the choice of treatment. In
breast cancer as in many other cancers the use of targeted agents is
overwhelming [18].
The search for a predictor that best describes the status of
axillary lymph nodes has been carried out for a long time in order to
predict prognosis and to plan the most appropriate therapeutic
strategy is very helpful the examination of the histopathological
and biological characteristics of each breast cancer. The extension
of surgery could have an impact on the well-being of physicians
apart from the stress induced by surgery-related complications
[19]. This effect can be added to the impact in the patient's quality
of life and clinical management. For this reason, a lot of studies have
tried to assess the most signiﬁcant parameters associated with the
presence of axillary lymph node metastases. The most important
predictors are the tumor size and the presence of lymphovascular
invasion, demonstrated by several univariate analyses. NewTable 2
Patients classiﬁcation into risk categories using cut off of 50%.




Patients with additional n
metastasis
50% (Low risk) 85 6
>50% (High risk) 90 72biomarkers could be useful in the selection of those patients who
are more suitable for axillary lymph node dissection. miRNAs are
emerging as potential diagnostic and prognostic biomarkers in
several malignancies [20]. According to a British study, the obser-
vation of those parameters could guide the surgeon in the choice of
the right treatment of the axilla, but none of them, individually
examined, can be considered a safe and useful marker for the se-
lection of patients to who didn't need ALND [21]. A recent publi-
cation has considered as important predictors the diameter of
tumor and lymphovascular invasion as together tumor localization
and multifocality. The locations at higher risk seem to be the ret-
roareolar and of course the external quadrants [22]. Moreover the
histological subtype of breast cancer and in particular the pattern of
gene expression are strongly connected with the presence of lymph
node metastases: recent evidences have estimated the luminal B
type at higher risk, followed by luminal A type. Both seem to be
characterized by an increased risk of additional nodal metastases in
patients with positive SLN, especially when compared to the “triple
negative” cancers, that very rarely spread to the axilla [23],
although they are burdened with a worse prognosis.
An important observation is that, except for the tumor site, all
the parameters above mentioned as signiﬁcant predictors of axil-
lary status are all covered by MSKCC nomogram. It offers the
advantage of processing all information about tumors and taking
into account the characteristics of each breast cancer it gives a
reliable estimate in terms of percentages of risk of nodal metastasis.
The factors that mostly inﬂuence the predictive model are lym-
phovascular invasion, tumor size, number of metastatic SLNs and,
as evidenced by the group that developed the nomogram, the
method of detection of metastasis. This shows the importance of
the accuracy of preoperative diagnostic techniques and of intra-
operative examination of the SLN that provide the information
required by the model.
Considering the current trend to make surgery as conservative
as possible, without betraying the principle of basic oncological
radicality, MSKCC nomogram is a tool characterized by great po-
tential in order to avoid an aggressive and unjustiﬁed intervention
such as ALND in patients with a positive SLN but at low risk of
additional axillary metastasis.
Literature shows that nowadays the choice of the cut off is
completely arbitrary and prospective studies are needed to deﬁne
an appropriate threshold value that divides the patients at high and
low risk of additional lymph node metastases. Previous retrospec-
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case series, including our own, nomogram predicted a probability
<10% in very few patients with positive SLN, then its use would
have a limited clinical impact. So our purpose was to establish a
higher cut off (50%), that in our series proved to be reasonably
reliable in assessing the risk of additional lymph node metastases.
If the nomogram had been applied to the 175 patients of the
sample as described above, 79 of the 97 womenwithout metastatic
involvement of axilla wouldn't have received ALND. Despite of the
rare complications of the intervention, to be always taken into
consideration, it's a great opportunity to have the possibility to
identify among the patients with SLN metastasis, those who actu-
ally beneﬁt from axillary surgery. The greatest advantage is that
MSKCC predictive model can be used immediately after the
communication of the result of intraoperative histopathological
examination of SLN and, thanks to the information derived from
preoperative ultrasound, mammography and core biopsy, it
immediately provides its probability of further nodal metastasis.
On the other hand, in 6 patients with small cancers (T1) inwhich
the probability obtained from nomogram was 50%, the histo-
pathological examination of the dissected lymph nodes showed the
presence of metastases. However those cancers had histopatho-
logical and biological features (low dimension, ERþ, PRþ,
Her2\neu-, etc.) that suggest a favourable prognosis. In all cases the
patients were treated with adjuvant radiotherapy and hormonal
therapy, which are effective means to check the locoregional and
systemic disease respectively.
ALND is currently assumed to be replaceable with other
locoregional ways of control of the disease in patients with clini-
cally negative axilla. Many trials demonstrated that patients
affected by T1/2N0 breast cancers treated with conservative sur-
gery, postoperative radiotherapy and adjuvant systemic therapy do
not beneﬁt from ALND [6,26]. Moreover, lymph nodes irradiation
instead of surgery seems to represent an effective alternative, as it
was shown in the annual meeting of the American Society of
Clinical Oncology (ASCO), in which the results of the trial AMAROS
[1] promoted by the European Organization for Research and
Treatment of Cancer (EORTC) were examined. This trial randomized
a sample of breast cancer patients with T1/2N0 tumors and positive
SLN in two groups: the ﬁrst had undergone ALND and the patients
of the second one had had radiotherapy addressed to the three
nodal levels of axilla and to medial supraclavicular lymph nodes.
After a 5 years follow-up, there are no signiﬁcant differences in
terms of axillary recurrence in both groups but a higher incidence
of complications in the group that had undergone ALND was
observed. Furthermore, we nowadays know little about the
possible difference in outcomes deriving from sentinel node biopsy
among female and male breast cancer patients [27].
Despite the encouraging results of the cited randomized trials,
guidelines are still unclear and surgeons usually still perform ALND
in case of SLNmetastasis. MSKCC nomogrammay represent a useful
tool and the role of ALND in patients with SLNmetastasis should be
reduced.
5. Conclusions
To sum up we have reason to believe that the application of
MSKCC monogram to the sample is a very reliable and usefull
predictive model in daily clinical practice. It's a tool that can add
important information to the intraoperative examination of the
SLN in order to guide the surgeon in choosing the most reasonable
treatment of axillary lymph nodes and represents a signiﬁcant
phase in the process towards a conservative treatment approach
that suggests the performance of axillary surgery only when
justiﬁed.Ethical approval
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